Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | PRKCI | P41743 | 3/20 | 0.35 |
| ▸ | AXL | P30530 | 3/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | CHUK | O15111 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371415 | 0.79 | HRH4 (0.49) | DYRK1AADORA2AADORA1PRKCITTBK1 | |
| SCHEMBL20748444 | 0.79 | ADORA2A (0.42) | DYRK1AADORA2AADORA1PRKCIAXL | |
| SCHEMBL5880789 | 0.79 | DYRK1A (0.38) | DYRK1AADORA2AADORA1PRKCIAXL | |
| SCHEMBL31514673 | 0.79 | PRKCI (0.41) | DYRK1AADORA2AADORA1PRKCIAXL | |
| SCHEMBL3126517 | 0.79 | ADORA2A (0.42) | DYRK1AADORA2AADORA1PRKCIAXL | |
| SCHEMBL161735 | 0.75 | ADORA2A (0.39) | DYRK1AADORA2AADORA1PRKCIAXL | |
| SCHEMBL30974906 | 0.75 | DYRK1A (0.35) | DYRK1AADORA2AADORA1PRKCIAXL | |
| SCHEMBL18701495 | 0.75 | DYRK1A (0.35) | DYRK1AADORA2AADORA1PRKCIAXL | |
| SCHEMBL7749921 | 0.74 | ADORA1 (0.55) | DYRK1AADORA2AADORA1AXLNUDT1 | |
| SCHEMBL256548 | 0.72 | DYRK1A (0.33) | DYRK1AADORA2AADORA1PRKCIAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2487036-B1 | MULTILAYERED OPTICAL FILM, AND PREPARATION METHOD THEREOF | SKC CO LTD (KR) | 2017-08-23 | — | — | EP | claimed |
| US-20120207993-A1 | MULTILAYERED OPTICAL FILM, AND PREPARATION METHOD THEREOF | SKC CO., LTD (KR) | 2012-08-16 | — | — | US | claimed |
| EP-2487036-A2 | MULTILAYERED OPTICAL FILM, AND PREPARATION METHOD THEREOF | SKC Co., Ltd (KR) | 2012-08-15 | — | — | EP | claimed |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | PFIZER, INC. (US) | 2011-11-24 | — | — | US | claimed |
| EP-1913000-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | Pfizer Products Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007012953-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | PFIZER PRODUCTS INC. (US) | 2007-02-01 | — | — | WO | claimed |
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| CN-117756806-A | Preparation method of tofacitinib intermediate | 山东新时代药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-3573992-B1 | SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF | TSANTRIZOS YOULA S (CA) | 2022-04-13 | — | — | EP | disclosed |
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | Tsantrizos, Youla S. (CA) | 2022-03-22 | — | — | US | disclosed |
| CN-113563342-A | LRRK2 inhibitors and methods of making and using the same | 达纳－法伯癌症研究所公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-107801397-B | LRRK2 inhibitors and methods of making and using the same | 达纳－法伯癌症研究所公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-107200741-B | Preparation method of anaplastic lymphoma kinase inhibitor | 首药控股(北京)有限公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-2007767-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R&D) LTD (GB) | 2008-12-31 | — | — | EP | disclosed |
| EP-1913000-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | Pfizer Products Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007012953-A2 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESIS | PFIZER PRODUCTS INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-0633886-A1 | PHARMACEUTICALLY ACTIVE BICYCLIC-HETEROCYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993020078-A1 | PHARMACEUTICALLY ACTIVE BICYCLIC-HETEROCYCLIC AMINES | THE UPJOHN COMPANY (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | GGPS1, TYMP, FDPS | DYRK1A 4604/4885ADORA2A 2865/4885ADORA1 3044/4885 |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | DPYD, CPS1, TYMS | DYRK1A 2937/4885ADORA2A 3457/4885ADORA1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.